Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | August 14, 2024 | August 16, 2024 |
| Myovant Sciences Ltd.MYOV · Entity 115677 | Director | October 26, 2016 | October 27, 2016 |
| Roivant Sciences Ltd.ROIV · Entity 3185 | Director | June 26, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date August 14, 2024 · Filed August 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 46,069 |
Ending reported balance
After 2024-08-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-14 · Exercise / conversion · Acquired 54,915 · Balance 54,915 F1: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. Row 2 · 2024-08-14 · Sale · Disposed 8,846 · Balance 46,069 F1: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.56 · Expires 2024-11-13 | Direct | 0 |
Reported balance
After 2024-08-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-14 · Exercise / conversion · Disposed 54,915 · Balance 0 F1: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. F2: This is a director stock option grant that is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold.
F2: This is a director stock option grant that is fully vested.
Myovant Sciences Ltd.
Report date October 26, 2016 · Filed October 27, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
Holding disclosure · report date 2016-10-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 F1: Does not include 37,231,342 shares owned by Roivant Sciences Ltd. ("Roivant"). Dr. Manchester is one of five directors of Roivant. Dr. Manchester expressly disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Does not include 37,231,342 shares owned by Roivant Sciences Ltd. ("Roivant"). Dr. Manchester is one of five directors of Roivant. Dr. Manchester expressly disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his pecuniary interest therein.
Roivant Sciences Ltd.
Report date June 26, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectHeld by QVT Financial Investment Cayman Ltd. | 13,689,166 |
Last balance in matching sequence
After 2026-06-30 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-06-26 · Sale · Disposed 300,783 · Balance 14,826,546 F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Row 2 · 2026-06-26 · Sale · Disposed 325,000 · Balance 14,501,546 F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Row 3 · 2026-06-29 · Sale · Disposed 200,000 · Balance 14,301,546 F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Row 4 · 2026-06-29 · Sale · Disposed 600,000 · Balance 13,701,546 F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Row 5 · 2026-06-30 · Sale · Disposed 12,380 · Balance 13,689,166 F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. |
| Common SharesSEC Table I · non-derivative | Direct | 1,748,403 |
Reported balance
After 2026-06-30 transaction · row 6
1 source rowRow 6 · 2026-06-30 · Sale · Disposed 200,000 · Balance 1,748,403 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2022 Filed Sep 20, 2022 01:53 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 71,850 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001140361-22-033880 · form4.xml · derivative · entry 6 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,850 Underlying: Common Shares · 71,850 shares Expires 2032-09-14 F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 15, 2022 Filed Sep 20, 2022 01:53 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 52,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-033880 · form4.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,142 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:10 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 41,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001447028-22-000033 · wf-form4_165359582944568.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Shares · 41,000 shares Expires 2032-05-25 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 25, 2022, the date of the grant. F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date of the grant. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:24 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001447028-21-000041 · wf-form4_162309747011064.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-03 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:57 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001447028-20-000064 · wf-form4_159104502505994.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-28 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 28, 2020, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| August 17, 2019 Filed Aug 20, 2019 20:16 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001447028-19-000052 · wf-form4_156633216383352.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. F2 · ownership.direct: Dr. Manchester is the Head of Life Sciences and a Portfolio Manager at QVT Financial LP and serves as a director on behalf of QVT Financial LP and its affiliates. Dr. Manchester holds these stock options for the benefit of certain funds managed by QVT Financial LP. Read SEC document |
| June 19, 2018 Filed Jun 22, 2018 21:01 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantDirector Stock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0001140361-18-029621 · doc1.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Shares · 22,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares underlying this option fully vested on June 19, 2018. F2 · ownership.direct: Dr. Manchester is the Head of Life Sciences and a Portfolio Manager at QVT Financial LP and serves as a director on behalf of QVT Financial LP and its affiliates. Dr. Manchester holds these stock options for the benefit of certain funds managed by QVT Financial LP. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:33 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001209191-17-041664 · doc4.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The shares underlying this option fully vested on June 21, 2017. F2 · ownership.direct: Dr. Manchester is the Head of Life Sciences and a Portfolio Manager at QVT Financial LP and serves as a director on behalf of QVT Financial LP and its affiliates. Dr. Manchester holds these stock options for the benefit of certain funds managed by QVT Financial LP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.